Prevention of HBV recurrence after liver transplant: The role of combination therapy

Digestive and Liver Disease Supplements

Volumn 3, Issue 4, 2009, Pages 98-103

  Buti, M ^a   Castells, L ^a   Campos, I ^a   Esteban, R ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Antiviral therapy; HBsAg; HBV prophylaxis; Hepatitis B immunoglobulins

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; ANTIVIRUS AGENT; ENTECAVIR; HEPATITIS B ANTIBODY; HEPATITIS B VACCINE; LAMIVUDINE; NUCLEOTIDE; TELBIVUDINE; TENOFOVIR;

ARTICLE; CLINICAL TRIAL; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOPROPHYLAXIS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LOW DRUG DOSE; PRIORITY JOURNAL; REINFECTION; RISK FACTOR; SURVIVAL RATE; UNSPECIFIED SIDE EFFECT; VIRUS LOAD; VIRUS REPLICATION; VIRUS RESISTANCE;

EID: 71649111917     PISSN: 15945804     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1594-5804(09)60035-8     Document Type: Article

References (46)

1. Samuel D. Liver transplantation for chronic hepatitis B. Gastroenterol Clin Biol 32 1 Pt 2 (2008) S25-S33
2. Ichai P., and Samuel D. Etiology and prognosis of fulminate hepatitis in adults. Liver Transpl 14 Suppl 2 (2008) S67-S79
3. Fontana R.J. Management of patients with decompensated HBV cirrosis. Semin Liver Dis 23 (2003) 89-100
4. O'Grady J.G., Smith H.M., Davies S.E., et al. Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications. J Hepatol 14 (1992) 104-111
5. Davies S.E., Portmann B.C., O'Grady J.G., et al. Hepatic histology following transplantation for chronic hepatitis B virus infection including a unique pattern of fibrosing cholestatic hepatitis. Hepatology 13 (1991) 150-157
6. Starzl T.E., Demetris A.J., and Van Thiel D. Liver transplantation. N Engl J Med 321 (1989) 1092-1098
7. Steinmuller T., Seehofer D., Rayes N., et al. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology 35 (2002) 1528-1535
8. Samuel D., Muller R., Alexander G., et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 329 (1993) 1842-1847
9. Kim W.R., Poterucha J.J., Kremers W.K., et al. Outcome of liver transplantation for hepatitis B in the United States. Liver Transplant 10 (2004) 968-972
10. Roche B., and Samuel D. Liver Transplantation for hepatitis B virus-related liver disease: indications, prevention of recurrence and results. J Hepatol 39 (2003) S181-S189
11. Marzano A., Gaia S., Ghisetti V., et al. Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence. Liver Transpl 11 (2005) 402-409
12. EASL Clinical Practice Guidelines: Management of chronic hepatitis B, 29 October 2008. J Hepatol 50 (2009) 227-242
13. Perrillo R., Rakela J., Dienstag J., et al. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Hepatology 29 (1999) 1581-1586
14. Villeneuve J.P., Condreay L.D., Willems B., et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 31 (2000) 207-210
15. Bain V.G., Kneteman N.M., Ma M.M., et al. Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation. Transplantation 62 (1996) 1456-1462
16. Bartholomew M.M., Jansen R.W., Jeffers L.J., et al. Hepatitis B virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 349 (1997) 20-22
17. Schiff E.R., Lai C.L., Hadziyannis S., et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre-and post-liver transplantation. Hepatology 38 (2003) 1419-1427
18. McMillan J.S., Shaw T., Angus P.W., et al. Effect of immunosuppressive and antiviral agents on hepatitis B virus replication in vitro. Hepatology 22 (1995) 36-43
19. Féray C., Zignego A.L., Samuel D., et al. Persistent hepatitis B virus infection in of mononuclear blood cells without concomitant liver infection. Transplantation 49 (1990) 1155-1158
20. Samuel D., Bismuth A., Mathieu D., et al. Passive immunoprophylaxis after liver transplantation in HBsAg positive patients. Lancet 337 (1991) 813-815
21. Müller R., Gubernatis G., Farle M., et al. Liver transplantation in HBs antigen (HBsAg) carriers: Prevention of hepatitis B virus (HBV) recurrence by passive immunization. J Hepatol 13 (1991) 90-96
22. Terrault N.A., Zhou S., Combs C., et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology 24 (1996) 1327-1333
23. Markowitz J.S., Martin P., Conrad A.J., et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 28 (1998) 585-589
24. Marzano A., Salizzoni M., Debernardi-Venon W., et al. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J of Hepatol 34 (2001) 903-910
25. Rosenau J., Bahr M.J., Tillmann H.L., et al. Lamivudine and low- dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection. J Hepatol 34 (2001) 895-902
26. Han S.H., Martin P., Edelstein M., et al. Conversion from intravenous to intramuscular hepatitis B immune globulin in combination with lamivudine is safe and cost-effective in patients receiving long-term prophylaxis to prevent hepatitis B recurrence after liver transplantation. Liver Transpl 9 (2003) 182-187
27. Seehofer D., Rayes N., Naumann U., et al. Preoperative antiviral treatment and postoperative prophylaxis in HBV-DNA positive patients undergoing liver transplantation. Transplantation 72 (2001 Oct 27) 1381-1385
28. Yao F.Y., Osorio R.W., Roberts J.P., et al. Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation. Liver Transpl Surg 5 (1999) 491-496
29. Yoshida E.M., Erb S.R., Partovi N., et al. Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low-dose hepatitis B immune globulin. Liver Transpl Surg 5 (1999) 520-525
30. Angus P.W., McCaughan G.W., Gane E.J., et al. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transpl 6 (2000) 429-437
31. McCaughan G.W., Spencer J., Koorey D., et al. Lamivudine therapy in patients undergoing liver transplantation for Hepatitis B virus precore mutant-associated infection: High resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low dose Hepatitis B immune globulin. Liver Transpl Surg 5 (1999) 512-519
32. Buti M., Mas A., Prieto M., et al. A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation. J Hepatol 38 (2003) 811-817
33. Hawkins A.E., Gilson R.J., Gilbert N., et al. Hepatitis B virus surface mutations associated with infection after liver transplantation. J Hepatol 24 (1996) 8-14
34. Ghany M.G., Ayola B., Villamil F.G., et al. Hepatitis B virus S Mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology 27 (1998) 213-222
35. Grellier L., Mutimer D., Ahmed M., et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 348 (1996) 1212-1215
36. Mutimer D., Pillay D., Dragon E., et al. High pretreatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft-reinfection after liver transplantation. J Hepatol 30 (1999) 715-721
37. Lo C.M., Cheung S.T., Lai C.L., et al. Liver transplantation in Asian patients with chronic hepatitis B using lamivudine prophylaxis. Ann Surg 233 (2001) 276-281
38. Perrillo R.P., Wright T., Rakela J., et al. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 33 (2001) 424-432
39. Schiff E., Lai C.L., Hadziyannis S., et al. Adefovir Dipivoxil Study 45 International Investigators Group. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl 13 (2007) 349-360
40. Naoumov N.V., Ross Lopes A., Burra P., et al. Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation. J Hepatol 34 (2001) 888-894
41. Neff G.W., Kemmer N., Kaiser T.E., et al. Combination therapy in liver transplant recipients with hepatitis B virus without hepatitis B immune globulin. Dig Dis Sci 52 (2007) 2497-2500
42. Buti M., Mas A., Prieto M., et al. Adherence to lamivudine after an early withdrawal of hepatitis B immune globulin plays an important role in the long-term prevention of hepatitis B virus recurrence. Transplantation 84 (2007) 650-654
43. Angus P.W., Patterson S.J., Strasser S.I., et al. A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis. Hepatology 48 (2008) 1460-1466
44. Lo C.M., Lau G.K., Chan S.C., et al. Efficacy of a pre-S containing vaccine in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B. Am J Transplant 7 (2007) 434-439
45. Sánchez-Fueyo A., Rimola A., Grande L., et al. Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: A new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation. Hepatology 31 (2000) 496-501
46. Angelico M., Di Paolo D., Trinito M.O., et al. Failure of a reinforced triple course of hepatitis B vaccination in patients transplanted for HBV-related cirrhosis. Hepatology 35 (2002) 176-181